Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.
Parienti
Jean-Jacques
JJ
Epidemiologie, Systemes d'Informations, Modelisation, Institut National de la Sante et de la Recherche Medicale U707, Paris, France. parienti-jj@chu-caen.fr
Massari
Veronique
V
Rey
David
D
Poubeau
Patrice
P
Verdon
Renaud
R
D000480:Alkynes; D048588:Benzoxazines / Q000008:administration & dosage / Q000009:adverse effects; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D003327:Coronary Disease / Q000139:chemically induced / Q000517:prevention & control; D018592:Cross-Over Studies; D003521:Cyclopropanes; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D050171:Dyslipidemias / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage* / Q000009:adverse effects; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016896:Treatment Outcome
D000480:Alkynes; D048588:Benzoxazines; D008078:Cholesterol, LDL; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; C098320:efavirenz